AB&B Bio-Tech Q3 2026 Net Profit Rises 16% to RMB 59 Million; Revenue Climbs to RMB 322 MillionPUBT·Nov 17, 2026 at 10:18 AM026270.00%
China CDE Approves IND Application for Ab&B Bio-Tech Tetanus Vaccine CandidateTip Ranks·Nov 13, 2026 at 01:10 PM026270.00%
Two Hong Kong Biotechs Have Their Approvals. Now Comes the Selling.Global Report·Oct 29, 2026 at 10:48 AM02565-3.72%026270.00%
Robot Joints, a Comb, and Who Collects the Rent in Hong KongGlobal Report·Oct 22, 2026 at 10:51 AM02391-4.75%00425-2.68%
Filed Under "Other": Eight Hong Kong Stocks With Almost Nothing in CommonGlobal Report·Oct 7, 2026 at 10:50 AM83690-3.85%020010.00%
The Ownership Question: Notes on Hong Kong's Uncovered TailGlobal Report·Sep 29, 2026 at 10:50 AM02546-0.67%03418-0.98%
Ab&B Bio-Tech Sets Out Board and Committee Structure to Bolster GovernanceTip Ranks·Sep 23, 2026 at 01:08 PM026270.00%
Ab&B Bio-Tech reshapes board and finance leadership amid trading suspensionTip Ranks·Sep 23, 2026 at 12:37 PM026270.00%
The Misfit Toys of Hong Kong Equities: Cash Kings, Bankruptcies, and Fake AI PivotsGlobal Report·Sep 15, 2026 at 11:33 AM02048-3.57%00022-4.85%
The Forgotten Periphery of Hong Kong Equities: A Tale of Two ExtremesGlobal Report·Sep 15, 2026 at 09:18 AM00999-2.72%026270.00%
Value, Pivots, and Pipelines: A Cross-Section of Hong Kong’s Disparate MarketGlobal Report·Sep 8, 2026 at 11:32 AM066600.00%023020.00%
HK Mid-Caps Diverge as China Feihe Revenues Surge While IGG Declares DividendGlobal Report·Sep 1, 2026 at 11:33 AM03818-0.83%026270.00%
Executive Sell-Offs and Web3 Pivots: Inside the Strategic Shifts Reshaping Hong Kong’s Mid-Cap LandscapeGlobal Report·Sep 1, 2026 at 09:17 AM03998-1.31%03818-0.83%
STOCKS | Hong Kong Exchange Lists Suspended CompaniesCoinLive·Aug 31, 2026 at 01:05 AM003180.00%01124+3.05%
The Asymmetry of Hong Kong's Market: Value Chain Reconfiguration from Consumer to Deep TechGlobal Report·Aug 25, 2026 at 11:33 AM02677+6.27%01351+8.51%